Vascular endothelial growth factor (VEGF) plays a central role in the development of several chorioretinal vascular disorders including exudative age-related macular degeneration (AMD). Detailed understanding of VEGF biochemistry has led to the development of four drugs which specifically inhibit its actions. Bevacizumab and ranibizumab have been the dominant ophthalmic anti-VEGF drugs for seven years and their regular use has significantly decreased vision loss. In late 2011, aflibercept, a high-affinity, fusion protein that acts as a soluble VEGF receptor, was approved for the treatment of exudative AMD. Phase three trials showed that monthly and bimonthly aflibercept maintained vision in 95 % of patients, improved average visual acuity by +8.3 to +9.4 letters, and thinned the macula comparably to monthly ranibizumab. Since its approval, aflibercept has been shown to decrease retinal edema and subretinal fluid, and flatten retinal pigment epithelial detachments in eyes that have responded incompletely to frequent ranibizumab and bevacizumab injections. Aflibercept's longer duration of action coupled with its comparable unit price (versus ranibizumab) promise to decrease the total cost of treatment.
nearly all patients (91-94 %) and improve vision in the majority. [10] [11] [12] [13] [14] Both drugs possess high binding affinities to all naturally occurring isoforms of VEGF-A (bevacizumab: K D =58-1,1000 pM to VEGF 165 ; ranibizumab: K D =46-192 pM to VEGF 165 ) [15] [16] [17] as well as the cleaved product VEGF 110 .
Aflibercept Development
Bevacizumab and ranibizumab are full-length antibody and antibody fragments, respectively, both of which were produced from a murine model. The scientists who created the VEGF Trap-eye or aflibercept (Eylea®, Regeneron, Tarrytown, NY), however, decided to employ a different binding strategy to neutralize diffusible VEGF-they created a soluble receptor molecule. Naturally occurring binding domains from native VEGF receptors were fused to the Fc (fragment crystallizable) backbone of a human IgG molecule. 18 The first or 'parent' VEGF-Trap (VEGF-Trap R1R1R1 ) contained the first three VEGF-binding domains from VEGF receptor one (VEGF R1 ). Since VEGFR1 has a higher binding affinity for VEGF 165 Figure 1) . 3, 4 Effective treatment for exudative AMD derived from what at first appeared to be an unlikely source -cancer research. Folkman (1971) 5 first proposed that tumor growth depended on a soluble angiogenesis factor and Senger (1983) 6 subsequently discovered the vasopermeability factor. Finally, two independent research groups isolated identical cytokines which became known as vascular endothelial growth factor (VEGF). 7, 8 This discovery kicked off two decades of intense research into the biochemistry of the VEGF families and resulted in the development of four drugs which specifically bind VEGF to prevent it from activating three trans-membrane receptors (VEGFRs 
Pre-clinical Trials
In pre-clinical studies aflibercept slowed the growth of orthotopic tumors in mice 19 and prevented luteal development in marmosets. 20 Aflibercept halted basic fibroblastic growth factor-induced corneal nevascularization, 21 extended the survival of high risk corneal grafts, 22 suppressed CNVM development in transgenic mice that secreted VEGF from their photoreceptors, 23 prevented laser-induced CNVM, 23 and prevented the development of matrigel-induced choroidal neovascular membranes in rats.
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Human Trials
These successes gave rise to early testing of aflibercept in patients with exudative AMD (see Table 1 ). In a dose-escalation trial, 25 25 patients were randomized to receive one of three intravenous doses of aflibercept (0.3 mg/kg, 1.0 mg/kg, or 3.0 mg/kg), followed by a four week observation period, and then three additional doses administered at two week intervals. Lower doses of aflibercept (0.3 mg/kg and 1.0 mg/kg) led to modest improvements in macular thinning (-10-66 %), whereas the highest dose (3.0 mg/kg) resulted in the greatest improvements in vision (+12 letters). Only patients who received 3 mg/kg had detectable serum levels of aflibercept at one month, suggesting that lower monthly doses were incapable of sustaining therapeutic blood levels. Unfortunately, two of the five patients receiving the highest dose experienced dose-limiting hypertension and proteinuria. Therefore, monthly intravenous administration of aflibercept appeared to be incapable of producing sustained therapeutic blood levels with an acceptable safety profile.
Due to concerns over systemic adverse events, aflibercept was No drug-related safety issues were identified and neither hypertension nor proteinuria was seen. The maximum tolerated intraocular dose of aflibercept was not determined.
The phase two CLEAR-IT 2 trial evaluated the 12-week effects of a fixeddose regimen of aflibercept. 27 Patients were randomized to receive Data from the early CLEAR-IT trials suggested that higher doses of aflibercept (> 0.5 mg) and three monthly loading doses produced the greatest improvements in vision and longest durations of clinical action.
Furthermore, clinically significant durations of action up to two and a half months had been predicted by mathematical modeling. 29 Therefore, investigators designed the double-masked, multi-center, active-control phase three VEGF trap-eye: investigation of efficacy and safety in wet wet age-related macular degeneration trials to include higher doses US OPHTHALMIC REVIEW of aflibercept (2 mg) and longer treatment intervals (two months). Regarding the major secondary endpoints, letters of vision gained and amount of macular thinning, there were no significant differences between aflibercept and ranibizumab treated patients. Average vision gains in each of the aflibercept treatment arms (+6.9 letters to +10.9 letters) were comparable to gains in the two ranibizumab arms (+8.1 letters and +9.4 letters). Compared to the ranibizumab arm, the only aflibercept treated group that gained significantly more letters was the 2 mg q4wk arm in the VIEW 1 (+8.1 vs. +10.9; p < 0.001), but this group improved the least (+6. Taken together, these results demonstrate that aflibercept possesses a longer duration of action than ranibizumab. Unfortunately, the 12-week capped PRN regimen did not enable an accurate determination of aflibercept's average duration of action. However, the data suggest that the aflibercept treatment intervals could be extended to an average of 13 weeks, compared to approximately 10 weeks for ranibizumab [Author Calculations], which is slightly longer than was seen in either the CATT13 or inhibit VEGF in age-related choroidal neovascularization (IVAN). 31 Thus it appears that aflibercept possesses a longer duration of action than ranibizumab-probably by three weeks-but not by a factor of two, as might be interpreted from the first year of the VIEW trials. Aflibercept has not been compared directly with bevacizumab, but since bevacizumab and ranibizumab performed comparably in head-to-head trials, 13, 31 aflibercept's head-to-head performance against bevacizumab would probably be similar to that with ranibizumab.
Post-Approval Experience
The favorable results from the first year of the VIEW trials convinced the The CLEAR-IT and VIEW trials suggest that extended duration of action is aflibercept's major therapeutic advantage, since injections can be administered every eight weeks while producing visual and anatomic results comparable to monthly ranibizumab. Previous attempts to extend ranibizumab intervals to three months led to steadily declining vision through one year, 32 and a 2-month hiatus after three monthly loading doses resulted in a loss of 3 to 4 letters. 33 A year of bimonthly aflibercept (after three loading doses) would save 42 % compared to monthly ranibizumab, though it would still cost nearly 400 % that of monthly bevacizumab. Most physicians, however, individualize therapy by using either PRN or treat-andextend strategies, both of which would allow fewer injections. Reasons for aflibercept's effectiveness as a salvage therapy are unclear but may include its high binding affinity to VEGF, binding of placental growth factor and VEGF-B, 100 % human protein composition, or tachyphyllaxis avoidance (see Figures 3a and 3b ). 
Summary and Future Use
Physicians' overall clinical impression of aflibercept for exudative AMD after the first year of use in the United States has been very positive.
Aflibercept has recently been granted regulatory approval in Australia, Japan, and Europe so it appears likely that its world-wide use will increase as physicians take advantage of its role as salvage therapy and increase its use as first-line treatment. n
